Caregivers' and Physicians' Treatment Preference in Parkinson Patients Treated With Neupro® Requiring Caregiver Support
NCT ID: NCT01330290
Last Updated: 2013-12-10
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
148 participants
OBSERVATIONAL
2011-03-31
2012-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
CROSS_SECTIONAL
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Neupro® Treatment
Routine treatment (2, 4, 6, 8, 10, 12, 14, 16 mg/24 hours) as per approved label in European Union (EU)/in accordance with the terms of the local marketing authorization for Neupro®
Neupro®
Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Neupro®
Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* The patients suffer from idiopathic Parkinson's Disease (iPD) treated with a combination of L-dopa or another oral iPD drug and Neupro® for at least one month
* The patients require caregiver support documented as per medical records (e.g. based on German level of care intensity 1 or greater)
* The decision to prescribe Neupro® must have been made by the physician independent of his/her decision to include the patient in the study
* And according to Summary of Product Characteristics (SmPC): Hypersensitivity to the active substance or to any of the excipients, magnetic resonance tomography (MRT) or cardioversion
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
UCB Pharma
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
UCB Clinical Trial Call Center
Role: STUDY_DIRECTOR
+1 877 822 9493 (UCB)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
52
Abensberg, , Germany
53
Alzenau in Unterfranken, , Germany
18
Beelitz-Heilstätten, , Germany
42
Bensheim, , Germany
24
Berlin, , Germany
27
Berlin, , Germany
37
Celle, , Germany
58
Cologne, , Germany
17
Dillingen, , Germany
48
Dresden, , Germany
32
Eisenach, , Germany
39
Erbach im Odenwald, , Germany
43
Erfurt, , Germany
60
Essen, , Germany
5
Gelnhausen, , Germany
40
Gelsenkirchen, , Germany
31
Göttingen, , Germany
38
Guelders, , Germany
29
Hagen, , Germany
57
Halle, , Germany
6
Halle, , Germany
28
Hamm, , Germany
47
Hanover, , Germany
7
Herborn, , Germany
55
Hoppegarten, , Germany
59
Jena, , Germany
50
Karlstadt am Main, , Germany
44
Königsbrück, , Germany
51
Lappersdorf, , Germany
8
Lohr, , Germany
4
Marktheidenfeld, , Germany
45
Merzig, , Germany
36
Minden, , Germany
34
Mittweida, , Germany
35
Mühldorf, , Germany
25
München, , Germany
41
München, , Germany
30
Münster, , Germany
49
Neuburg am Inn, , Germany
21
Neumarkt, , Germany
13
Niederschöna, , Germany
9
Oschatz, , Germany
54
Schorndorf, , Germany
2
Schriesheim, , Germany
1
Stralsund, , Germany
12
Stratroda, , Germany
15
Stuttgard, , Germany
33
Stuttgart, , Germany
20
Ulm, , Germany
14
Unterhaching, , Germany
22
Weil am Rhein, , Germany
11
Westerstede, , Germany
23
Wolfach, , Germany
56
Wolfratshausen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sieb JP, Themann P, Warnecke T, Lauterbach T, Berkels R, Grieger F, Lorenzl S. Caregivers' and physicians' attitudes to rotigotine transdermal patch versus oral Parkinson's disease medication: an observational study. Curr Med Res Opin. 2015 May;31(5):967-74. doi: 10.1185/03007995.2015.1030376.
Related Links
Access external resources that provide additional context or updates about the study.
FDA Safety Alerts and Recalls
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SP0939
Identifier Type: -
Identifier Source: org_study_id